CASE STUDY | ADVERTISING
When Oncology Launch Required Immediate Impact, We Activated from Day One.
THE CHALLENGE
Launching in an Oncology Market Defined by Low Confidence and Competitive Pressure
An oncology biotech launched a therapy in relapsed/refractory acute myeloid leukemia, a high-risk setting defined by frequent relapse, poor outcomes, and low physician confidence.
As a second-to-market entrant, the brand needed to establish relevance quickly in a complex and competitive oncology landscape. Physicians faced frustration with limited durability of existing treatments, reinforcing hesitation in adopting new therapies.
The challenge extended beyond introducing a new treatment. It required an oncology launch strategy capable of shifting perception, engaging priority HCP audiences, and delivering coordinated impact from day one.
THE BREAKTHROUGH
An Integrated Oncology Launch Grounded in Scientific Storytelling and Connected Engagement
BGBx recognized that in a high-need oncology treatment setting with low physician confidence, success depended on a strategy capable of reshaping perception, aligning scientific narrative, and executing with precision.
We built a unifying creative platform centered on optimism as a source of power, reframing the narrative to deliver a more motivating and actionable perspective for HCPs, shaping the brand identity, messaging, and execution across the launch.
The approach integrated:
- Coordinated non-personal promotion across branded and unbranded messaging
- Paid search, endemic and non-endemic display, custom email, and targeted sponsorships
- Precision NPI-level targeting and scalable digital activation
- Dynamic creative optimization and message evolution
- Launch readiness across HCP and DTC websites, media, field materials, and national sales meeting support
This integrated oncology launch strategy aligned messaging, channels, and targeting to deliver a coordinated and high-impact market entry.
THE RESULTS
From Approval to Activation in Hours, Surpassing Oncology Launch Expectations
Within hours of FDA approval, branded messaging was deployed across media channels and partners to rapidly drive HCP awareness. Coordinated activation cascaded launch messaging across paid search, display, custom email, and targeted sponsorships, reaching priority HCP audiences with speed and precision.
The campaign exceeded first-quarter sales goals within one month of launch, while ongoing multichannel activation maintained engagement and expanded reach beyond the initial launch.
16,000+
Website Visits
92% new users
~7,600
Target HCPs
Reached with strong engagement
2–3x
CTR Performance
Above benchmarks
Our Perspectives on Advertising
2026 Oncology Market Access Trends
Implications of the IRA’s Maximum Fair Price (MFP) Negotiations
340B Drug Discount Program
Let’s Plan Your Next Oncology Launch Strategy
At BGBx, we design integrated pharmaceutical launch strategies that connect scientific storytelling, HCP engagement, and digital activation, ensuring your brand reaches the right audiences with clarity, consistency, and measurable impact.
